Wake Forest University School of Medicine Develops Digital Platform to Better Care for Stroke Patients

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

CAMBRIDGE, MA -- June 30, 2022 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

Blackford Announces Partnership with Us2.ai For Advanced Echo Interpretation

EDINBURGH, SCOTLAND - JUNE 29, 2022 - Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their partnership to bring advanced echocardiography analysis tools to the Blackford Platform. The Blackford Platform enables the seamless selection and integration of AI applications into medical imaging workflows, which supports the complex measurement and reporting needs of clinicians.

NuProbe Closes $50M in New Fundraising

Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing NuProbe investors Sequoia Capital China, Biotrack Capital, and Yonghua Capital and new investors Pappas Capital, Haoreng Capital, and Deguan Capital also participated in the round. CEC Capital served as the financial advisor for this fundraising. The funds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies.

Us2.ai Secures US$15M Series A To Improve Detection of Cardiovascular Disease

SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced it has raised US$15 million in a series A round led by IHH Healthcare and Heal Partners, with participation from Pappas Capital and existing investors including Sequoia India, EDBI and Partech Ventures. The new funds will be used to drive Us2.ai’s ambitious growth targets for clinical implementation in the US, Europe and Asia, as well as the expansion of commercial activities with leading pharmaceutical companies, research labs, and imaging providers worldwide.

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Treatments for Solid Tumors

SAN DIEGO, Jan. 10, 2022 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo® (nivolumab).

Under the terms of the agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combination therapies using two of BioAtla's Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio. BioAtla will serve as the study sponsor and will be responsible for costs associated with the trial execution. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study.

FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder

MORRISVILLE, N.C., Nov. 08, 2021 -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that YUTREPIA has met all regulatory standards for quality, safety and efficacy required for approval in the United States.